Browsing by Author "Corbalan, Ramon"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Cardiac dyssynchrony correlates with left ventricular remodeling after myocardial infarction
    (SOC MEDICA SANTIAGO, 2009) McNab, Paul; Castro, Pablo; Gabrielli, Luigi; Verdejo, Hugo; Carlos Quintana, Juan; Rodriguez, Jose A.; Corbalan, Ramon
    Background: Cardiac dyssynchrony is common in advanced heart failure (HF), but the changes in cardiac synchrony after myocardial infarction (MI) have not been adequately described. Aim: To study the relationship between cardiac synchrony and left ventricular remodeling after acute myocardial infarction. Material and methods: Forty nine patients aged 59+/-10 years (77% men) with a first episode of a ST segment elevation MI were studied. Scintigraphic left ventricular function and synchrony analyses were performed at baseline and after a six months follow-up. Determinations were compared with 33 healthy subjects. Results: At baseline, patients with MI had a decreased left ventricular ejection fraction (LVEF) and significant dyssynchrony, when compared with controls. LVEF was 36.4%+/-10%, left ventricular end-diastolic volume (LVEDV) 127+/-38 mL, interventricular delay (IEV) 29+/-35 milliseconds (ms), and intraventricular delay (IAV), 234+/-89 ms. After 6 months, LVEF significantly improved (38%+/-10%, p = 0.042) without significant changes in LVEDV (129+/-32 mL, p = 0.97), IEV (24+/-17, p = 0.96) or IAV (231 +/- 97, p = 0.34). At baseline there were significant correlations between IAV and LVEF, and between IAV and LVEDV (r = -0.48, p = 0.001 and r = -0.41, p = 0.004, respectively). These correlations remained significant after 6 months. There was a positive correlation between IAV and LVEDV changes at six months (r = 0.403, p = 0.04). Conclusions: The development of cardiac dyssynchrony correlates with adverse left ventricular remodeling after MI (Rev Med Chile 2009; 137: 1457-62).
  • No Thumbnail Available
    Item
    Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF
    (2021) Blumer, Vanessa; Rivera, Manuel; Corbalan, Ramon; Becker, Richard C.; Berkowitz, Scott D.; Breithardt, Gunter; Hacke, Werner; Halperin, Jonathan L.; Hankey, Graeme J.; Mahaffey, Kenneth W.; Nessel, Christopher C.; Piccini, Jonathan P.; Hellkamp, Anne S.; Singer, Daniel E.; Fox, Keith A. A.; Patel, Manesh R.
    Background ROCKET AF demonstrated the efficacy and safety of rivaroxaban compared with warfarin for the pre-vention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). We examined baseline characteristics and outcomes in patients enrolled in Latin America compared with the rest of the world (ROW).